Market Study Reports Secukinumab Emerged as a Leading Treatment for HS
To gauge the impact and evolving landscape of HS treatment post-secukinumab approval, Spherix Global Insights conducted research with more than...
To gauge the impact and evolving landscape of HS treatment post-secukinumab approval, Spherix Global Insights conducted research with more than...
Despite the expanded armamentarium, Cosentyx has not impacted dermatologists’ perceived unmet need for new HS treatment options, according to Spherix...
US dermatologists’ perceptions and experience with Sotyktu likely impacting their take on the entire TYK2 class for the treatment of...
Bariticinib (Olumiant; Eli Lilly) is prescribed by the majority of US dermatologists to their patients with alopecia areata (AA), according...
Despite little prescriber differentiation between the JAKs, including satisfaction and manufacturer perceptions, Olumiant is projected to maintain a significant market...
Boehringer Ingelheim’s Cyltezo has a slight competitive edge over other concurrent biosimilar launches on certain key performance metrics, though prescriber...
Amgen’s $13.4 billion Otezla bet can withstand competition from Bristol Myers Squibb’s Sotyktu. That is the conclusion of analysts at...
Despite the increased efficacy of BMS’ Sotyktu over Amgen’s Otezla, dermatologists continue to express a desire for additional oral agents...
After early adoption, overall use of Olumiant in alopecia areata is beginning to level-off, according to Spherix Global Insights Exton,...
April 3, 2023 Skylar Jeremias Although rheumatologists, dermatologists, and gastroenterologists rated their awareness of adalimumab biosimilars as high, a significant...
Amgen’s Otezla likely to face the most immediate impacts of increased Sotyktu adoption EXTON, Pa., December 8, 2022 /PRNewswire/ — On...
Despite highly favorable perceptions of the first approved treatment, dermatologists’ desire increased support from Eli Lilly sales representatives EXTON, Pa.,...